Skip to main content

Table 3 Fractions of stable mutants (< 1 kT) from codons 96 to 289 before and after substitution.

From: Structural and functional implications of p53 missense cancer mutations

 

G

A

V

L

I

S

C

T

M

F

Y

W

H

K

R

D

E

N

Q

ALL

A

2/4

 

5/6

  

3/4

 

6/7

 

0/1

     

3/7

   

0.655

V

1/12

1/12

 

6/12

5/6

   

1/8

1/5

 

0/3

   

2/5

0/9

  

0.24

L

  

5/9

 

2/3

1/1

  

1/5

3/6

  

1/4

 

1/8

   

0/6

0.33

I

  

0/6

3/4

 

0/6

 

0/6

1/3

0/6

0/1

    

0/1

 

0/6

 

0.10

S

7/7

3/3

 

1/2

4/5

 

11/11

10/10

 

6/7

1/3

  

0/1

4/6

  

3/5

 

0.67

C

1/8

0/1

   

3/10

 

1/1

 

0/7

2/9

0/8

0/1

 

1/10

  

0/1

 

0.14

T

 

9/10

  

9/11

3/8

  

2/3

    

3/5

1/2

  

3/6

 

0.67

M

  

5/6

4/5

5/6

  

2/5

     

1/6

1/4

    

0.56

F

0/1

 

1/4

1/5

1/3

1/5

0/4

   

2/2

        

0.25

Y

0/1

    

0/6

0/6

  

5/5

  

0/7

0/1

 

0/7

 

0/6

0/1

0.125

W

0/1

  

0/1

 

0/1

0/1

       

0/1

    

0.0

H

  

1/1

3/5

      

5/7

   

2/6

2/6

 

2/4

3/6

0.51

K

   

1/1

   

3/3

2/3

  

0/1

  

4/5

 

2/4

3/4

2/3

0.71

R

3/15

  

11/12

1/3

4/13

5/9

2/4

1/2

0/1

1/2

0/6

5/10

3/4

   

0/2

3/8

0.43

D

3/7

3/3

6/8

 

1/1

     

5/8

 

4/7

 

0/1

 

6/7

7/8

 

0.70

E

4/11

6/9

8/10

1/2

         

4/11

0/1

6/10

  

4/8

0.53

N

    

7/8

8/9

 

7/7

1/1

0/1

2/6

 

3/6

4/6

 

6/8

   

0.73

Q

   

3/5

        

5/6

3/4

5/6

 

2/2

  

0.78

ALL

0.31

0.58

0.62

0.63

0.76

0.365

0.52

0.74

0.36

0.38

0.47

0.0

0.44

0.47

0.38

0.43

0.45

0.43

0.375

 
  1. First column shows residues before mutation and first row shows residues after mutation. Each element means fraction of stable mutations. Elements with 100% stable mutations are highlighted in bold. The last column shows the percentage of total stable mutations from a given WT amino acid. The last row shows the percentage of total stable mutations to a given amino acid. See Table 2 for more detail.